"","analysisId","nctId","pValue","statisticalMethod","studyType","EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","outcomeTitle","outcomeType","groupDescription","conditionIds","briefTitle","has_less_than","N","model","I","R","C","JAB"
"1","04f8529e63a017fda3a52d14db4d11d2","NCT00023595",0.009,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"H01: KCCQ Symptom Stability","SECONDARY",NA,"D006333; D002318; D006331; D003327","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",FALSE,1194,"mann_whitney",NA,NA,NA,1.14336521708696
"2","05bbf20a4308fdde29bb7a225a39b604","NCT01638000",0.009,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12","SECONDARY","Week 12 (≥1 point improvement) Odds Rato vs. Mirabegron","D053201; D014570; D001745","A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.",FALSE,1747,"logistic_regression",NA,NA,NA,1.381772317663
"3","0762d788d30bea044e9f39b55989b6f5","NCT02528188",0.006,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 4: \>=70% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,1.02602381662469
"4","079e25c5fa0d4770351b4722417bbbe3","NCT02528188",0.0059,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Meeting Outcome Measures in Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Responder Index at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 4","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1998,"logistic_regression",NA,NA,NA,1.0116180724855
"5","0e3cdc7c0fed523b8575350a066a49b5","NCT02528188",0.0079,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 4: \>=50% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1998,"logistic_regression",NA,NA,NA,1.31483938037962
"6","0ee92e13f4634d01b148f2122962b3dd","NCT00094302",0.01,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Potassium","SECONDARY","Since the p-value for the preceding test (Statistical Analysis 1) was not significant at the 0.05 level, another generalized linear model was fit, omitting the interaction between treatment group and month of visit. This tests whether the value of the post-baseline laboratory parameter differs by treatment group, taking into account that measurements in the same subject over time may be correlated.","D006333; D002318; D006331","Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function",TRUE,3445,"linear_regression",NA,NA,NA,2.12942984619502
"7","0fbd6baec27178049c0e5901e354b893","NCT00337727",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Patients Who Reported Complete Response","SECONDARY",NA,"D009325; D014839","Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)",TRUE,832,"logistic_regression",NA,NA,NA,1.04964838595516
"8","11052175734cc6a84a54644c9365937e","NCT00556374",0.007,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With New or Worsening Vertebral Fractures","SECONDARY",NA,"D001943","Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy",FALSE,1644,"logistic_regression",NA,NA,NA,1.07054865380522
"9","118f1e14a7c8b5b11e370195c6aae47f","NCT02528188",0.0077,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 8: \>=70% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,1.28370859508888
"10","1275bf5f32a561db3fa165ddcb342e6b","NCT05012163",0.002,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Flu Vaccination at Appointment","PRIMARY","Null hypothesis: There is no difference in vaccination rates between patients sent messages offering $1 cash in exchange for vaccination and those sent no study messages; Alternative hypothesis: the vaccination rate is higher in patients sent messages offering $1 cash compared to those who were not sent messages.","D007251","Lottery Incentive Nudges to Increase Influenza Vaccinations",FALSE,28792,"linear_regression",NA,NA,NA,1.43236139635449
"11","12ebe3f1c4559797ed7143162cf29d46","NCT01236053",0.0049,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,17853,"logistic_regression",NA,NA,NA,2.55280962895913
"12","19dccecb9ee38e5112f3aa2dc3b46dce","NCT03258645",0.01,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Previous Modified Rankin Scale (mRS) at First Ever Ischaemic Stroke According to Dabigatran Initiation Time Period","SECONDARY","Univariate linear regression with the continuous dependent variable of time-to-initiation for dabigatran in days and independent variable of Modified Rankin Scale (mRS) at index date was applied.","D001281","This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke",FALSE,1240,"linear_regression",NA,NA,NA,1.27974442537769
"13","1a2f2e28e943bca0664521dc36f48c1b","NCT01236053",2e-04,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,1.29789263256815
"14","1a5ac4f36696f4edcf350047cc750508","NCT05127304",0.007,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"COPD or Pneumonia-attributable Health Care Resource Utilization","PRIMARY","Other medical visits","D029424","A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",FALSE,11316,"linear_regression",NA,NA,NA,2.80337301464238
"15","1c04f1881064c7c09b27807593ea5110","NCT01459653",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Modeling FN Episode: Cycle Level","SECONDARY","History of anaemia at enrollment as patient-level predictor for FN episode","D009101; D009503; D064147; D000084462; D005334","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",FALSE,1273,"logistic_regression",NA,NA,NA,1.29657154396284
"16","1e3a0142fec482f616a94def478f741f","NCT02889796",0.009,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With no Radiographic Progression From Baseline at Week 24","SECONDARY","Filgotinib 200 mg vs Placebo at Week 24 for change in mTSS ≤ 0.","D001168; D001172","Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate",FALSE,950,"logistic_regression",NA,NA,NA,1.02061821357177
"17","1e675c7bb4cfa1d1265fda5801adf360","NCT01001234",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Pain Freedom at 2 Hours Post Dose in Participants Between 6 and 17 Years of Age","SECONDARY","The comparison of rizatriptan versus placebo with respect to pain freedom at 2 hours post Stage 2 dose for participants between 6 and 17 years of age was conducted using a logistic regression model with factors for treatment, Stage 2 baseline pain severity (moderate or severe), age (6 to 11 years old or 12 to 17 years old), and region (US or ex-US). Model-derived odds ratio and a two-sided p-value were provided. An odds ratio \>1 is in favor of the rizatriptan group.","D008881","A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)",FALSE,770,"logistic_regression",NA,NA,NA,1.01010605604897
"18","1fe0f4ced1d312b6ee4cde7efc679867","NCT04148989",0.005,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Antibiotic Utilization'","OTHER_PRE_SPECIFIED","Differences-in-differences analysis using multivariable logistic regression to estimate the change in outcome after versus before intervention implementation at the intervention site adjusted for the change observed at control sites and for prespecified covariates.","D018805; D014115; D004630","Effects of Code Sepsis Implementation on Emergency Department (ED) Sepsis Care",FALSE,180402,"logistic_regression",NA,NA,NA,8.26288695498596
"19","2224c4553bd4f324d3beaa40be69e951","NCT01236053",0.002,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,20382,"logistic_regression",NA,NA,NA,1.20522964988748
"20","23a71a9b9005e72d07a172bf91647a4e","NCT02528253",0.0088,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 12, \>=70%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1011,"logistic_regression",NA,NA,NA,1.0317486938692
"21","23d4abf648caa29057cbf5fea9491087","NCT01881373",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Prevalence of Acanthosis Nigricans","PRIMARY","intervention vs control. The children from each community recruited each time were NOT the same children. The number of communities is consistent across time.","D000052; D009765; D056128","Children's Healthy Living Community Randomized Trial",TRUE,3987,"logistic_regression",NA,NA,NA,2.29052474927477
"22","2546574178cc7232e8633ded4ffebd6c","NCT03932799",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Satisfaction With Pain-related Treatment","SECONDARY","* Primary predictor is binary (1 for Washington, 0 for Ohio)
* Models survey weighted
* Robust variance estimates","D009293","Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing",FALSE,2295,"logistic_regression",NA,NA,NA,1.73888007679412
"23","29d70d17926c0c9dfb94f17985f7af80","NCT00556374",0.0088,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With New Vertebral Fractures","SECONDARY",NA,"D001943","Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy",FALSE,1644,"logistic_regression",NA,NA,NA,1.31395862272312
"24","2c1f77c83ca702ec9828b1155d855ec4","NCT00094302",0.01,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Quality of Life, as Measured by the Kansas City Cardiomyopathy Questionnaire.","SECONDARY","Since the p-value for the preceding test (Statistical Analysis 1) was not significant at the 0.05 level, another generalized linear model was fit, omitting the interaction between treatment group and month of visit. This tests whether the value of the post-baseline quality of life parameter differs by treatment group, taking into account that measurements in the same subject over time may be correlated.","D006333; D002318; D006331","Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function",TRUE,3445,"linear_regression",NA,NA,NA,2.12942984619502
"25","2e910ceb223289c84698ee11242ea0db","NCT02605174",0.009,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free","PRIMARY",NA,"D008881","Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",FALSE,1026,"logistic_regression",NA,NA,NA,1.06037546625596
"26","3103c1cdf8db340528907f371feaf0b0","NCT05493787",0.003,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Number of Patients Who Self-scheduled a Flu Shot","PRIMARY","Null hypothesis: Flu shot self-scheduling does not differ between those sent an Active Control message and those not sent a message (i.e., those in the Passive Control group); Alternative hypothesis: Sending an Active Control message increases self-scheduling compared with sending no message. Analysis combines across November and December send dates.",NA,"Nudging Flu Vaccination by Making it Easy for Patients to Schedule a Flu Shot",FALSE,46510,"linear_regression",NA,NA,NA,2.63813386516389
"27","326e2b905c6b7568f8ba256e06d6cd1e","NCT00023595",0.008,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"H01: All-cause Mortality Within 30 Days After Randomization","SECONDARY",NA,"D006333; D002318; D006331; D003327","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",FALSE,1212,"logistic_regression",NA,NA,NA,1.03684043806229
"28","34ff9de565eaac65db89cb74bb1c0d2e","NCT01416194",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Clinical Fractures","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",TRUE,7777,"logistic_regression",NA,NA,NA,3.19773018380892
"29","38b9198089b30d9b0d4919562a6fc59a","NCT01444430",0.004,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Percent of Nights With Awakening(s) Due to Asthma","SECONDARY",NA,"D001249","A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents",FALSE,11580,"anova",2,NA,NA,1.71081104782295
"30","38d5edd0de1045eea743a0fef70c6d92","NCT04172701",0.0093,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Costs: Outpatient Medical Costs (Per Person Per Month)","SECONDARY",NA,"D029424","A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)",FALSE,4888,"t-test",NA,NA,NA,2.3769471949384
"31","391226cfb0c0dfac54e264c0a0bd33d3","NCT01070550",0.0088,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for BMI in kg/m\^2. The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including total cumulative dose of peginterferon and ribavirin), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,2981,"logistic_regression",NA,NA,NA,1.76768632301629
"32","4073ff4be9054e3e245d00ff1fa84c85","NCT01236053",0.0062,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,30.8971533278091
"33","42089f11d604bb6aac6a0d3043db7e40","NCT01381406",0.007,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Incidence Rate Per 100 Person Years of Hospitalization or Emergency Department (ED) Visit Related to Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)","PRIMARY",NA,"D008171; D008173; D029424","Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations",FALSE,3333,"logistic_regression",NA,NA,NA,1.5226018423453
"34","4317394dc84f638612ee8e3a878795ce","NCT01459653",0.0079,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Predictors of Absolute Neutrophil Count","PRIMARY","Study drug dose (higher vs lower) as predictor for ANC","D009101; D009503; D064147; D000084462; D005334","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",FALSE,1185,"logistic_regression",NA,NA,NA,1.01381861788458
"35","4331567a2d28d8ae1471aa122e2736ae","NCT02100631",0.0062,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Mean Fold Change in Vibriocidal Antibody Titer Between Day 1 and Day 11","OTHER_PRE_SPECIFIED",NA,"D002771","A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults",FALSE,2978,"t-test",NA,NA,NA,1.29064690541302
"36","4855ee8037cddbf4f1d3f3a88d708d23","NCT01631214",0.008,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24","SECONDARY",NA,"D010024","Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis",FALSE,3659,"logistic_regression",NA,NA,NA,1.79803889692901
"37","48fe777d351bc77046c7d7c3f2f65414","NCT01416194",0.01,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Renal Failure","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",TRUE,7777,"linear_regression",NA,NA,NA,3.19773018380892
"38","4ae21792c10ae68b89f112418bb8a63a","NCT04684836",0.01,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Unplanned Hospital Admissions From the ED","PRIMARY","Difference-in-differences model","D008173; D029424; D006333","Comparative Effectiveness of Telemedicine in Primary Care",TRUE,33100,"linear_regression",NA,NA,NA,6.59489724428277
"39","4e2a66f6cb4772cd4c5d1007089a0c4b","NCT01070550",0.0074,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for age per 10 years. The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including total cumulative dose of peginterferon and ribavirin), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,2981,"logistic_regression",NA,NA,NA,1.51376848627711
"40","4e69af9ebde6fd69aad5d16aa5a7b060","NCT03958071",0.0048,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Baseline Patient Characteristics: Age","PRIMARY",NA,"D011658; D054990; D005355","A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking",FALSE,12917,"t-test",NA,NA,NA,2.13147003243213
"41","4ffabed91b3fe41ff5d8d3bf915fde1f","NCT01087541",0.01,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Glycosylated Haemoglobin A1c at 6 Months","PRIMARY",NA,"D003920","SEGUDIAB Study: Evaluation of Safety in the Diabetic Patients",TRUE,6830,"t-test",NA,NA,NA,2.99689691879371
"42","5004b27cc4b73572a47dec917e9a0395","NCT00279201",0.009,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"INITIATION: Rate of Self-reported Hypoglycemic Episodes","SECONDARY",NA,"D003920; D003924","The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)",FALSE,2050,"anova",2,NA,NA,1.49637904803928
"43","52d9a8846526b6d524d188bb2a10b3d1","NCT02528188",0.006,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Meeting Outcome Measures in Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Responder Index at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 8","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,1.02602381662469
"44","533ead8c3d40cf06ed4ba055f6775dd0","NCT01138124",0.0053,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D002292; D007680; D010386; D010195; D050500; D012148","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",FALSE,30026,"logistic_regression",NA,NA,NA,3.5536613586909
"45","54597b48bf56620ddf4330858b65a69a","NCT01138124",0.0031,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin","PRIMARY",NA,"D010190; D002292; D007680; D010386; D010195; D050500; D012148","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",FALSE,19046,"logistic_regression",NA,NA,NA,1.73969022761229
"46","573589d6dd48237eca9148446f8dd308","NCT01263015",0.01,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Plasma Human Immunodeficiency Virus -1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 96 and Week 144","SECONDARY",NA,"D000163; D015658","A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)",FALSE,833,"mann_whitney",NA,NA,NA,1.05027396748098
"47","582c8c4a5dac81f6b18193773635bb1b","NCT01236053",0.0012,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,6.89716543035013
"48","587321ea09ba08dc00f8075359097e3a","NCT03716869",0.006,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Subgroup Analyses Based on School District Demographic Data","OTHER_PRE_SPECIFIED",NA,"D003866; D003863; D003865","Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder",FALSE,12909,"logistic_regression",NA,NA,NA,2.60642925477263
"49","5981cad8aed9256057efd0ea9524de81","NCT01066793",0.0089,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for on-treatment response (pEVR \[Partial Early Virological Response\] vs No RVR/EVR). The logistic regression analysis for mSVR was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,960,"logistic_regression",NA,NA,NA,1.0157612089616
"50","5bcb074c3d91e45c4a483d378ec716d8","NCT02528253",0.0085,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 40, \>=90%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1012,"logistic_regression",NA,NA,NA,1.00077425573849
"51","5c6ec2ab1fcf4b782c53b2f41fbb8720","NCT04323137",0.0035,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Flu Vaccination Rate","PRIMARY","This analysis compared all groups that were informed they were high risk (High risk only, High risk based on medical records, High risk based on algorithm) to control patients who were not sent a message.

Null hypothesis: informing patients they are high risk for flu and flu-related complications does not increase flu vaccination rate; Alternative hypothesis: informing patients they are high risk for flu and flu-related complications increases flu vaccination rate",NA,"Encouraging Flu Vaccination Among High-Risk Patients Identified by ML",FALSE,38598,"logistic_regression",NA,NA,NA,2.76573583909715
"52","5e585187ade8a1af436491ea27c4c7e6","NCT02528188",0.008,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 4: \>=30% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1989,"logistic_regression",NA,NA,NA,1.32673972673106
"53","6332ecd8706220c19e116017f10f661d","NCT04289623",0.007,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Rate of Enrollment (14 Days)","PRIMARY","We conducted a logistic regression among the previously enrolled group with the standard email as the reference group.",NA,"Assessing the Impact of myHealth Rewards Program-related Communications on Enrollment: Replication",FALSE,13021,"logistic_regression",NA,NA,NA,3.00703382766504
"54","65b8f9e7405a85ecffd657f84a74f6f5","NCT04381481",0.01,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Number of Teaspoons of Added Sugar Participants Think the Fruit Drink Contains (Fruit Drink Experimental Task 1)","SECONDARY","Beverages with claim compared to control beverage","D063766","Studying the Impact of Product Packaging in a Virtual Store Environment",TRUE,1515,"linear_regression",NA,NA,NA,1.41386458182062
"55","66389dcd9cf3a8bb91bae24301a0ff04","NCT00094302",0.01,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Sodium","SECONDARY","Since the p-value for the preceding test (Statistical Analysis 1) was not significant at the 0.05 level, another generalized linear model was fit, omitting the interaction between treatment group and month of visit. This tests whether the value of the post-baseline laboratory parameter differs by treatment group, taking into account that measurements in the same subject over time may be correlated.","D006333; D002318; D006331","Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function",TRUE,3445,"linear_regression",NA,NA,NA,2.12942984619502
"56","68f42732f943134955b75a252cdef8b2","NCT00099359",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Risk Factors for Perinatal HIV-1 Transmission","SECONDARY",NA,"D015658; D000163","Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission",FALSE,1591,"logistic_regression",NA,NA,NA,1.44874236808248
"57","6c9d371e1750a7e5f95cf18b5f9ce3bf","NCT01416194",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Ischemic Stroke","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",TRUE,7777,"logistic_regression",NA,NA,NA,3.19773018380892
"58","796ba78111d9dc7ef5dc0773b2e8d86a","NCT04381481",0.01,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Appeal of Fruit Drink (Fruit Drink Experimental Task 1)","SECONDARY","beverages with claim compared to control beverage","D063766","Studying the Impact of Product Packaging in a Virtual Store Environment",TRUE,2192,"linear_regression",NA,NA,NA,1.69952696756211
"59","7ab7b452f927b4325c3ef2ac7c48481d","NCT04547192",0.006,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Appropriate Use of Key Performance Indicators in Initial Assessment and Management of the Injured at Non-tertiary Hospitals in Ghana","PRIMARY","Tetanus Considered for bites, burns, lacerations, and abrasions","D000066553","Improving Initial Management of the Injured at Ghanaian District and Regional Hospitals With a Trauma Intake Form",FALSE,4077,"linear_regression",NA,NA,NA,1.46570014552785
"60","7bbf5de079e8fced5f1bbeee61827534","NCT01368185",0.01,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Diastolic Blood Pressure (DBP)","SECONDARY","Comparison between Month 3 and Baseline","D006973","Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)",TRUE,1705,"t-test",NA,NA,NA,1.49953882648572
"61","7ea0e19e781340696105210339dc28a6","NCT01881373",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Prevalence of Acanthosis Nigricans","PRIMARY","Intervention vs control comparing 24 months to baseline.","D000052; D009765; D056128","Children's Healthy Living Community Randomized Trial",TRUE,5645,"logistic_regression",NA,NA,NA,2.72481930777285
"62","7fec4eaa1844d9b19c40da527fbf6dbb","NCT01881373",0.009,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Waist Circumference","PRIMARY","The children from each community recruited each time were NOT the same children. The number of communities is consistent across time.","D000052; D009765; D056128","Children's Healthy Living Community Randomized Trial",FALSE,3987,"linear_regression",NA,NA,NA,2.08514706909587
"63","8180a499ceb9ad3e3f35f614182a5b7d","NCT01638000",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Improvement in Symptom Bother Score as Assessed by the OAB-q: ≥ 10 Points Improvement in OAB-q at Week 12 and Final Visit","SECONDARY","Week 12 Odds Ratio vs. Mirabegron","D053201; D014570; D001745","A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.",FALSE,1833,"logistic_regression",NA,NA,NA,1.55459672277149
"64","82d2c8d7801b2ea1e1a660c8fc86e107","NCT02528253",0.0092,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 8, \>=30%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1012,"logistic_regression",NA,NA,NA,1.07401255203274
"65","8326d8bc2ecbf84e92dbf8390c6a0372","NCT04547192",0.006,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Appropriate Use of Key Performance Indicators in Initial Assessment and Management of the Injured at Non-tertiary Hospitals in Ghana","PRIMARY","Airway assessed","D000066553","Improving Initial Management of the Injured at Ghanaian District and Regional Hospitals With a Trauma Intake Form",FALSE,4077,"linear_regression",NA,NA,NA,1.46570014552785
"66","8aa195c7b36f0642aa30c7b4aafa3933","NCT01236053",0.0046,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,20382,"logistic_regression",NA,NA,NA,2.57597139139188
"67","8d01a7042c045b7cbb33fbf6be312f3a","NCT04172701",0.0062,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"All-cause Healthcare Resource Utilization (HCRU): Number of Inpatient Visits (Per Person Per Month)","SECONDARY",NA,"D029424","A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)",FALSE,4888,"mann_whitney",NA,NA,NA,1.65271227124242
"68","8d2eaba75a68276644fd6cf6b9075ffe","NCT01773733",0.002,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Adverse Events","SECONDARY",NA,"D009765","The PRIMAVERA Study: Reduxine Safety Monitoring in Patients With Alimentary Obesity",TRUE,69810,"t-test",NA,NA,NA,2.23014546895094
"69","8ee02c83b816319b930e382ae5a3ace2","NCT05127304",0.003,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"COPD or Pneumonia-attributable Health Care Costs (Insurer + Patient Paid Amounts)","PRIMARY","Outpatient visits costs","D029424","A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",FALSE,11316,"linear_regression",NA,NA,NA,1.30166137514094
"70","91ecd13bec6ebeb55a404f1ccc12dc97","NCT00279201",0.006,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"INITIATION: Rate of Self-reported Hypoglycemic Episodes","SECONDARY",NA,"D003920; D003924","The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)",FALSE,2050,"anova",2,NA,NA,1.04027780967844
"71","932710adc4a358137a92e93b4d89961c","NCT02896400",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Tobacco Abstinence","PRIMARY","8 arms including BNI (BNI only, BNI+NRT, BNI+QL, BNI+Text, BNI+NRT+QL, BNI+NRT+Text, BNI+QL+Text, BNI+NRT+QL+Text) compared to the 8 arms that do not include BNI (Control, NRT only, QL only, Text only, NRT+QL, NRT+Text, QL+Text, NRT+QL+Text)","D014029","Optimizing Tobacco Dependence Treatment in the Emergency Department",FALSE,1053,"logistic_regression",NA,NA,NA,1.17986665608715
"72","9361371adea3600937183f5ebc2a06bd","NCT01416194",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Cardiac Disorders","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",FALSE,7777,"logistic_regression",NA,NA,NA,3.19773018380892
"73","936f1684f0413f8e324fa8f323db7132","NCT00091507",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Cardiac Arrest or Acute Mortality","SECONDARY",NA,"D006333; D002318; D006331; D009203; D003327; D000789; D007238","IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.",FALSE,871,"logistic_regression",NA,NA,NA,1.07377606522841
"74","956efe292be5c31cbff8b58a493a1a08","NCT02528253",0.0093,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Low Back Pain From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/ Last Observation CF (LOCF)","SECONDARY","Week 16: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline PGA of low back pain, baseline average LBPI, and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1012,"logistic_regression",NA,NA,NA,1.08441401128004
"75","97698c6fdc69503b3ecd7a0553ed82dc","NCT01416194",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Venous Thromboembolism (VTE)","PRIMARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",TRUE,7777,"logistic_regression",NA,NA,NA,3.19773018380892
"76","99b74509f76ca4bbf68b2a6e2b67a244","NCT02465515",0.003,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change in Estimated Glomerular Filtration Rate (eGFR) Calculated Using Modification of Diet in Renal Disease (MDRD) Formula","SECONDARY",NA,"D003920; D003924","Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",FALSE,9432,"t-test",NA,NA,NA,1.18846720911115
"77","9bdd08b4ab83c65bb72dac0f44a25f47","NCT04172701",0.0091,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"All-cause Healthcare Costs: Outpatient Medical Costs (Per Person Per Month)","SECONDARY",NA,"D029424","A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)",FALSE,4888,"t-test",NA,NA,NA,2.33128060000249
"78","9d367e9b10951cb6a1b0bdf5bab56e85","NCT01368185",0.01,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Systolic Blood Pressure (SBP)","SECONDARY","Comparison between Month 3 and Baseline","D006973","Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)",TRUE,1705,"t-test",NA,NA,NA,1.49953882648572
"79","9f12ef5a162137470ca78eeb39f1c668","NCT01416194",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Biliary Events","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",TRUE,7777,"logistic_regression",NA,NA,NA,3.19773018380892
"80","a028759dd263ae5ac386790af23557d4","NCT01236053",0.0033,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,17.4515838842603
"81","a086089357ffc267469570ca038f2434","NCT01631214",0.008,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With New Vertebral Fractures Through Month 12","SECONDARY",NA,"D010024","Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis",FALSE,3399,"logistic_regression",NA,NA,NA,1.73310705050442
"82","a0df77c29a8e11f942f643901666054b","NCT00949884",0.0096,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Participants Achieving Blood Pressure Goals at Week 8","OTHER_PRE_SPECIFIED","Percentage of participants achieving diastolic blood pressure goal of \<80 mmHg","D006973","Olmesartan Comparison to Losartan in Hypertensive Subjects",FALSE,850,"logistic_regression",NA,NA,NA,1.02299787627187
"83","a0f75a9a1e87e059970e0bdd0ed0edcb","NCT00023595",0.01,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"H02: Seattle Angina Questionnaire (SAQ) Anginal Frequency Subscale","SECONDARY",NA,"D006333; D002318; D006331; D003327","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",FALSE,970,"mann_whitney",NA,NA,NA,1.13271769496004
"84","a260634ef2740f9f16dc9334d2385ed9","NCT01138124",0.0095,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin","PRIMARY",NA,"D010190; D002292; D007680; D010386; D010195; D050500; D012148","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",FALSE,19046,"logistic_regression",NA,NA,NA,4.77941922316343
"85","a4752041dc6488b13b258df0ade24d0e","NCT04381481",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Percent of Participants Who Selected Apple-flavored Fruit Drink (Fruit Drink Experimental Task 1)","SECONDARY","beverages with claim compared to control beverage","D063766","Studying the Impact of Product Packaging in a Virtual Store Environment",TRUE,2219,"logistic_regression",NA,NA,NA,1.70993042143803
"86","a686ade7e65ef5162dec7dd69120e91a","NCT02306122",0.01,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Duration of Nonadherence Event","PRIMARY",NA,"D006937","Pharmacy Home Adherence Reporting and Monitoring Outcomes Study",TRUE,956,"linear_regression",NA,NA,NA,1.12457005606209
"87","a9cc696bcfdeaa48fbdad9aa3430f5c1","NCT01236053",0.0019,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,20382,"logistic_regression",NA,NA,NA,1.14979083623068
"88","ac6e6790cff3027f599462ef038c7f1e","NCT01070550",0.0071,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for AST ratio at BL (\> 1.5 vs \<=1.5). The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including total cumulative dose of peginterferon and ribavirin), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,2981,"logistic_regression",NA,NA,NA,1.4585973850124
"89","ad53538adb80f2c000e4ad8b7c7f704d","NCT01138124",0.0042,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D002292; D007680; D010386; D010195; D050500; D012148","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",FALSE,30026,"logistic_regression",NA,NA,NA,2.87892363995787
"90","af0eaf8918497f98864f02a2e958d05a","NCT01138124",0.0015,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D002292; D007680; D010386; D010195; D050500; D012148","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",FALSE,30026,"logistic_regression",NA,NA,NA,1.12273711620794
"91","b338670a08530daea2563b54c961a882","NCT01236053",8e-04,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,4.73824365385732
"92","b641d3e7379df254f271122495a9c17b","NCT01416194",0.01,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of All Malignancies","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",TRUE,7777,"linear_regression",NA,NA,NA,3.19773018380892
"93","b718a883aece9aea10cefcb62cbc1afa","NCT05401149",0.007,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Distribution of Modified Rankin Scale (mRS) Score at 1 Year","SECONDARY",NA,"D020521","Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients",FALSE,1560,"logistic_regression",NA,NA,NA,1.04296450750662
"94","b99459d1a643d1464ae4e6d6f4224f74","NCT01138124",0.0034,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D002292; D007680; D010386; D010195; D050500; D012148","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",FALSE,19046,"logistic_regression",NA,NA,NA,1.8924365962416
"95","bb627ac6da9d544ef5e00ceb8929b98b","NCT01972841",0.009,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 3 Diary Days at Weeks 4, 8, 12 and EoT","SECONDARY","Odds ratio from a logistic regression model including treatment group, sex, age group (\<65, \>=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.","D053201; D014570; D001745","This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",FALSE,1242,"logistic_regression",NA,NA,NA,1.16599222821441
"96","bd4340a8e5adc9b94329d62baa76b67a","NCT01070550",0.0062,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for cumulative ribavirin dose per 10000 mg, first 12 weeks. The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,2981,"logistic_regression",NA,NA,NA,1.29129519806126
"97","bd44883391a9cb88c1a9bb244ab28f53","NCT01236053",0.0024,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,20382,"logistic_regression",NA,NA,NA,1.42443668212094
"98","be1dbd754aae92e9b918554dc7494848","NCT00144339",0.0069,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 12","SECONDARY",NA,"D008171; D029424","Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients",FALSE,4807,"anova",2,NA,NA,1.80446577668772
"99","c0f38fb347134735a9ad81f49275fbe2","NCT01337336",0.009,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Number of the Indicated COPD-related Exacerbations","SECONDARY",NA,"D008171; D008173; D029424","Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population",FALSE,4001,"t-test",NA,NA,NA,2.08879851249057
"100","c1cbc951e8158bc30b1b3edd83ae97d3","NCT00443560",0.01,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Duration of Labor Analgesia","SECONDARY",NA,"D048949","The Association Between Decreasing Labor Analgesia Epidural Infusion and Forceps Delivery",TRUE,2072,"mann_whitney",NA,NA,NA,1.65249718004833
"101","c3dfa217a8b2d4b87b20f3c942375f89","NCT01972841",0.009,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, at Least 10 Points Improvement on OAB-q Symptom Bother Scale and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT","SECONDARY","Odds ratio from a logistic regression model including treatment group, sex, age group (\<65, \>=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q symptom bother scale and baseline PPBC as covariates.","D053201; D014570; D001745","This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",FALSE,1242,"logistic_regression",NA,NA,NA,1.16599222821441
"102","c51ad7c42d125ac145258aeba4b21230","NCT03930732",0.0089,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With SGRQ Improvement >=4 Points at Week 52","SECONDARY","Derived from logistic regression model which includes treatment group, region (pooled country), ICS dose, smoking status at screening, and baseline SGRQ total score as covariates. Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).","D008171; D008173; D029424; D007249","Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation",FALSE,939,"logistic_regression",NA,NA,NA,1.00466996376581
"103","c6fe8998ef066fa905776340943fe66d","NCT02266277",0.0026,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Reliant Medical Group (RMG) Patients With Electronic Health Record (EHR) Documentation of Influenza Vaccine Completion for 2014/2015 Season","PRIMARY",NA,"D007251; D011008","System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts",FALSE,10000,"logistic_regression",NA,NA,NA,1.07379248329479
"104","c7d720bc6d630e6e13ddc6231f8aff73","NCT01416194",0.01,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Thyroid Disorders- Goitre","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",TRUE,3831,"linear_regression",NA,NA,NA,2.24534283552016
"105","cb6ea43d028742a55ec952e30aa8df30","NCT04364165",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"HIV Testing Uptake","PRIMARY",NA,"D000163; D015658","Effect of U=U Messaging on HIV in South Africa",FALSE,1048,"logistic_regression",NA,NA,NA,1.1770798124339
"106","cb8df7e6df3328cc2e5f307c325f8148","NCT01138124",0.0026,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","PRIMARY",NA,"D010190; D002292; D007680; D010386; D010195; D050500; D012148","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",FALSE,19046,"logistic_regression",NA,NA,NA,1.48159231840286
"107","cd38dd57581d46f19568a3c0bd45bd91","NCT01459653",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Modeling CIN/FN-related Chemotherapy Disturbance: Cycle Level","SECONDARY","Center type: academic-affiliated vs non-academic as center-level predictor for CIN/FN-related chemotherapy disturbance","D009101; D009503; D064147; D000084462; D005334","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",FALSE,1045,"logistic_regression",NA,NA,NA,1.17540453489891
"108","cdc692fde87bc1c8eb3b85824c8fb3e4","NCT00094302",0.01,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Depression Symptoms, as Measured by Patient Health Questionnaire.","SECONDARY","Since the p-value for the preceding test (Statistical Analysis 1) was not significant at the 0.05 level, another generalized linear model was fit, omitting the interaction between treatment group and month of visit. This tests whether the value of the post-baseline quality of life parameter differs by treatment group, taking into account that measurements in the same subject over time may be correlated.","D006333; D002318; D006331","Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function",FALSE,1477,"linear_regression",NA,NA,NA,1.39609899161573
"109","d1738ea0ae2e098dc732820e636790b3","NCT01236053",0.008,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,20382,"logistic_regression",NA,NA,NA,4.24032164916455
"110","d870808bcfa93edd59dfa49b19262d1a","NCT00094302",0.01,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Serum Creatinine","SECONDARY","Since the p-value for the preceding test (Statistical Analysis 1) was not significant at the 0.05 level, another generalized linear model was fit, omitting the interaction between treatment group and month of visit. This tests whether the value of the post-baseline laboratory parameter differs by treatment group, taking into account that measurements in the same subject over time may be correlated.","D006333; D002318; D006331","Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function",TRUE,3445,"linear_regression",NA,NA,NA,2.12942984619502
"111","db36289e27b7d7c845bcf159c2ece011","NCT02528188",0.0076,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants Who Withdrew Due to Lack of Efficacy","SECONDARY","OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline diary average pain, baseline WOMAC pain score, classification variables index joint, highest Kellgren-Lawrence grade, NSAID and treatment.","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1998,"logistic_regression",NA,NA,NA,1.27002998195102
"112","def75ff921e6174003c7253a830b5d4c","NCT01416194",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Hypertriglyceridemia","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",TRUE,7777,"logistic_regression",NA,NA,NA,3.19773018380892
"113","df74a228c17ef750f46c6eed7c859b2c","NCT02528188",0.0068,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 4: \>=50% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,1.14827382129998
"114","e1a305d124062b3d4c33ac2ff4e290cb","NCT01066793",0.0092,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for HCV RNA at BL in log10 (IU/mL). The logistic regression analysis for relapse was performed for association between treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,960,"logistic_regression",NA,NA,NA,1.04624539778613
"115","e20c22cc3e3b72e3d6f995bc17929974","NCT01416194",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Clinical Fractures","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",FALSE,3831,"logistic_regression",NA,NA,NA,2.24534283552016
"116","e2602fe136fb064e228d3d88d749d873","NCT05018689",0.006,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in University of Michigan Depression Center Peer-to-Peer Depression Awareness Assessment Perceptions of School Culture Scores From Baseline (1 of 8)","SECONDARY","I would try to stay away from the new student",NA,"Evaluation of the Aevidum Curriculum and Club",FALSE,2557,"linear_regression",NA,NA,NA,1.16139296334341
"117","e381041a801873cfade4fe4281723bc4","NCT01236053",0.0063,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,2067,"logistic_regression",NA,NA,NA,1.09146218028265
"118","e3d2ab3bd1dd54684e5e89f8856d11eb","NCT02605174",0.008,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Phonophobia Free","OTHER_PRE_SPECIFIED",NA,"D008881","Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",FALSE,1174,"logistic_regression",NA,NA,NA,1.02055274190717
"119","e7affd7a2ccc144b66b29f3a9d2029c0","NCT01368185",0.01,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Serum Uric Acid (SUA) Level","PRIMARY","Comparison between Month 3 and Baseline","D006973","Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)",TRUE,1705,"t-test",NA,NA,NA,1.49953882648572
"120","e9d71652b54c4fcb24ee4d0abf396c69","NCT00331773",0.009,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Frequency of Patients With GU and GI Acute and Late Toxicity","SECONDARY","Late GU toxicity rates were tabulated and dichotomized as \< grade 2 vs ≥ grade 2. To evaluate the differences by treatment arm, 2 X 2 subtables were formed and relative risk (RR) estimates with 95% CIs were computed.","D011471","Radiation Therapy in Treating Patients With Stage II Prostate Cancer",FALSE,1079,"logistic_regression",NA,NA,NA,1.08724090557538
"121","ead1ced08b2ae1f5be20c89787cf67f4","NCT02528188",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 2: \>=50% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,1.62119639165769
"122","eb3c747e48bdf474696d7a0a2db81cc9","NCT01070550",0.0069,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for aspartate aminotransferase (AST) ratio at BL (\> 1.5 vs \<=1.5). The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,2981,"logistic_regression",NA,NA,NA,1.42165605633074
"123","eca193d4e389a5a14b58f376a962dfdd","NCT05481216",0.009,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"HIV Viral Load","PRIMARY","Conditional logistic regression models accounting for case-control matching will be used to identify risk factors for advanced immunodeficiency associated with COVID-19.","D000086382; D060085","HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV",FALSE,1492,"logistic_regression",NA,NA,NA,1.277377875623
"124","eec7a54cb28e2815a280348a1f9be879","NCT04196777",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Cases Who Were Re-admitted to the Hospital or Presented to an Emergency Department or an Urgent Care Clinic","SECONDARY","To model this secondary outcome across all sites, we used a logistic regression model and a set of four explanatory variables: time, a binary indicator for an observation occurring within the intervention phase, an interaction term between these two main effects (time and intervention), and a binary indicator for the primary outcome.","D014570; D064420","Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists",TRUE,1797,"logistic_regression",NA,NA,NA,1.53931074268959
"125","ef761b880070b230949f59256b1af9ec","NCT03965754",0.005,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Enrollment (7 Days)","PRIMARY","We conducted a logistic regression with the two experimental conditions as dummy variables with the standard email as the reference group (among employees who previously enrolled in the program).",NA,"Assessing the Impact of myHealth Rewards Enrollment Emails",FALSE,2850,"logistic_regression",NA,NA,NA,1.03997867274304
"126","efde5b9bf4c91875d49aaa088dc2e9d1","NCT04332614",0.0055,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Email Opened: Control vs. Less-is-better vs. Social Proof vs. Endowment","SECONDARY",NA,NA,"Email Campaign to Increase Uptake of myGeisinger",FALSE,4191,"logistic_regression",NA,NA,NA,1.37389590849306
"127","f2d67e708b88ce8e935774ce6e9d09f9","NCT02306122",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Probability of Resolution of Nonadherence Within 30 Days","PRIMARY",NA,"D006937","Pharmacy Home Adherence Reporting and Monitoring Outcomes Study",TRUE,956,"logistic_regression",NA,NA,NA,1.12457005606209
"128","f317ed14510333e5f066d36d42ff8175","NCT05493787",0.003,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Number of Patients Who Self-scheduled a Flu Shot","PRIMARY","Null hypothesis: Flu shot self-scheduling does not differ between those sent a Protect Yourself - Rare message and those not sent a message (i.e., those in the Passive Control group); Alternative hypothesis: Sending a Protect Yourself - Rare Message increases self-scheduling compared with sending no message. Analysis combines across November and December send dates.",NA,"Nudging Flu Vaccination by Making it Easy for Patients to Schedule a Flu Shot",FALSE,46468,"linear_regression",NA,NA,NA,2.63694266266651
"129","f35db23e840ff4bb5555922a5f9d99da","NCT00337727",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Patients Who Reported No Vomiting","PRIMARY",NA,"D009325; D014839","Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)",TRUE,831,"logistic_regression",NA,NA,NA,1.04902243141389
"130","f4452d3c1c635a31ed14fe77eaf7e112","NCT01236053",0.0066,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,20382,"logistic_regression",NA,NA,NA,3.5680634312401
"131","fd6d2d15fda88313f91f0c9f42ea3756","NCT02297815",0.008,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Health Related Quality of Life Score","PRIMARY","Propensity-score based full matching performed using patient and physician-level characteristics. Average treatment effect weights calculated and applied to a weighted linear regression.","D007239; D012852; D010612; D010033","Comparative Effectiveness of Antibiotics for Respiratory Infections",FALSE,2430,"linear_regression",NA,NA,NA,1.46599376751479
